ABSTRACT
BACKGROUND: The prognosis of patients with advanced heart failure is unfavourable. However, little is known about the survival of patients referred for heart transplantation but finally disqualified from transplantation due to contraindications. This study aimed to evaluate the prognosis of patients' disqualified from heart transplantation. METHODS: It was a retrospective study based on medical records of patients disqualified from heart transplantation. RESULTS: One hundred and fifty-one patients were included and 94 deaths were recorded during long-term follow-up (range 0.02-10.1 years). The survival rate at 5 years was 25%. The mean age of the studied population was 57.7 years and the majority of patients were males, 87.4%. The ischaemic aetiology (66.2%) was the most dominant aetiology of heart failure. In the Cox regression model, supervision by the specialist cardiology centre (HR 0.61;p = 0.04) and pharmacotherapy with beta-blockers (HR = 0.47;p = 0.02) positively influenced the prognosis. On the contrary, well-known heart failure risk factors like a renal failure (HR 1.59;p = 0.049), pulmonary hypertension (HR 1.55;p = 0.046), liver failure (HR 2.65;p = 0.02) were negative predictors of outcome. By Kaplan-Meier analysis, patients with other than pulmonary hypertension causes of disqualification from heart transplantation had a better survival rate, p = 0.047. CONCLUSIONS: The prognosis of patients disqualified from heart transplantation is unfavourable. However, some of the patients experience relatively long survival. Therefore, careful clinical assessment and identification of factors influencing prognosis may improve adequate patients' qualifications for heart transplantation.
Subject(s)
Heart Failure , Heart Transplantation , Hypertension, Pulmonary , Heart Failure/diagnosis , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Risk FactorsABSTRACT
BACKGROUND: Organizational and educational activities in primary care in Poland have been introduced to improve the chronic heart failure (CHF) management. OBJECTIVES: To assess the use of diagnostic procedures, pharmacotherapy and referrals of CHF in primary care in Poland. METHODS: The cross-sectional survey was conducted in 2013, involving 390 primary care centres randomly selected from a national database. Trained nurses contacted primary care physicians who retrospectively filled out the study questionnaires on the previous year's CHF management in the last five patients who had recently visited their office. The data on diagnostic and treatment procedures were collected. RESULTS: The mean age ± SD of the 2006 patients was 72 ± 11 years, 45% were female, and 56% had left ventricular ejection fraction <50%. The percentage of the CHF patients diagnosed based on echocardiography was 67% and significantly increased during the last decade. Echocardiography was still less frequently performed in older patients (≥80 years) than in the younger ones (respectively 50% versus 72%, Ρ <0.001) and in women than in men (62% versus 71%, P <0.001). The percentage of the patients treated with ß-blocker alone was 88%, but those with a combination of angiotensin inhibition 71%. The decade before, these percentages were 68% and 57%, respectively. Moreover, an age-related gap observed in the use of the above-mentioned therapy has disappeared. CONCLUSION: The use of echocardiography in CHF diagnostics has significantly improved in primary care in Poland but a noticeable inequality in the geriatric patients and women remains. Most CHF patients received drug classes in accordance with guidelines.
Subject(s)
Echocardiography/methods , Healthcare Disparities , Heart Failure/drug therapy , Primary Health Care/methods , Age Factors , Aged , Aged, 80 and over , Chronic Disease , Cross-Sectional Studies , Echocardiography/statistics & numerical data , Female , Health Care Surveys , Heart Failure/diagnosis , Humans , Male , Middle Aged , Poland , Primary Health Care/statistics & numerical data , Referral and Consultation/statistics & numerical data , Retrospective StudiesABSTRACT
BACKGROUND The aim of this study was to find the main risk factors for development of cardiac allograft vasculopathy (CAV), especially factors identified before the surgical procedure and factors related to the recipient profile and the medical history of the donor. MATERIAL AND METHODS There were 147 patients who had heart transplantation (HT) included in this study: mean age was 45.8±15.3 years. All study patients had coronary angiography after HT. Analyzed risk factors were: non-immunologic recipient risk factors (age of transplantation, smoking, hypertension, lipids, diabetes, obesity and weight gain after HT), immunologic recipient risk factors (acute cellular rejection (ACR), acute humoral rejection (AMR), cytomegalovirus (CMV) episodes), and donor-related risk factors (age, sex, catecholamine usage, ischemic time, compatibility of sex and blood groups, cause of death, cardiac arrest). RESULTS CAV was recognized in 48 patients (CAV group); mean age 53.6±13.6 years. There were 99 patients without CAV (nonCAV group); mean age 48.3±15.5 years. A univariate Cox analysis of the development of coronary disease showed statistical significance (p<0.05) for baseline high-density lipid (HDL), ACR, AMR, CMV, and donor age. Multivariate Cox regression model confirmed that only baseline HDL, episodes of ACR, donor age, and CMV infection are significant for the frequency of CAV after HT. CONCLUSIONS Older donor age is highly associated with CAV development. Older donor age and low level of HDL in heart recipients with the strongest influence of immunologic risk factors (ACR, CMV infection) were linked with development of CAV.
Subject(s)
Graft Rejection/prevention & control , Heart Diseases/etiology , Heart Transplantation/adverse effects , Immunosuppressive Agents/therapeutic use , Adult , Age Factors , Coronary Angiography , Female , Heart Diseases/diagnostic imaging , Heart Diseases/prevention & control , Humans , Male , Middle Aged , Risk FactorsABSTRACT
BACKGROUND: Optimal management of heart failure (HF) patients is crucial to reduce both mortality and the number of hospital admissions, at the same time improving patients' quality of life. AIM: The aim of the study was to assess the quality of care of hospitalised patients with HF in Poland in 2013 and compare it with the results of a similar survey performed in 2005. METHODS: The presented study was conducted from April to November 2013 in a sample of 260 hospital wards in Poland, recruited by stratified proportional sampling. Similarly to the first study edition in 2005, a trained nurse contacted physicians, who filled out the study questionnaires on the last five patients with HF, who had been discharged from an internal or cardiological ward. HF did not have to be a major cause of hospital admission. RESULTS: The mean age of the 1300 hospitalised patients was 72.1 years, an increase of 2.3 years since the 2005 survey. The proportion of patients classified as New York Heart Association IV decreased from 28.5% in 2005 to 22.1% in 2013. In comparison with 2005, more patients had concomitant disorders such as hypertension (79.5% vs. 71.0%), diabetes (46.2% vs. 33.2%), and chronic renal failure (33.4% vs. 19.4%). Access to echocardiography has improved in recent years: it was available for 98.9% of the surveyed hospital wards (93% in 2005) and it was performed during the hospitalisation in 60.2% of the patients (58.8% in 2005). In 2013 N-terminal pro-B-type natriuretic peptide was accessible for 80.8% of hospital wards (12.8% in 2005) and the test was performed in 31.3% of the hospitalised patients (3.3% in 2005). Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB) were administered in 68.9% of HF discharged patients, beta-blockers in 84.8%, mineralocorticoid receptor antagonist (MRA) in 57.9%, diuretics in 85.9%, and digoxin in 23%. The respective numbers in 2005 were 85.9%, 76.0%, 65.4%, 88.9%, and 38.4%. The decrease in prescription of ACEI or ARB resulted from lesser usage of these drugs in internal medicine wards (from 84.3% in 2005 to 55.6% in 2013). CONCLUSIONS: In comparison to the analogous project run in 2005, an improvement in some areas of HF treatment was observed in Polish hospitals, such as accessibility to echocardiography and natriuretic peptide measurement as well as beta-blocker and MRA use. At the same time, a meaningful decrease in ACEIs or ARBs usage in internal wards was observed, which might be the result of the ageing of the HF population and an increased number of comorbidities.
Subject(s)
Cardiology Service, Hospital/standards , Heart Failure/therapy , Adrenergic beta-Antagonists , Aged , Aged, 80 and over , Comorbidity , Echocardiography , Female , Health Services Accessibility/trends , Heart Failure/diagnosis , Heart Failure/epidemiology , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Poland , Retrospective Studies , Surveys and QuestionnairesABSTRACT
BACKGROUND: Pulmonary hypertension (PH) is recognised in about 60% of patients referred for heart transplantation (HTx), and it influences the patient's prognosis. AIM: To assess the prognostic value of reactive PH in patients listed for elective HTx. METHODS: A total of 522 patients were enlisted from the Polish National Registry (POLKARD), listed for HTx, in whom complete haemodynamic data were reported. The endpoint was all-cause death before HTx. Heart transplantation, elective or urgent, was considered as an end of the follow-up (mean follow-up 1.47 ± 1.26 years). Patients were divided into three subgroups: no PH, passive PH, reactive PH taking into account mean pulmonary artery pressure (PAP) of 25 mm Hg, pulmonary capillary wedge pressure (PCWP) 15 mm Hg, and pulmonary vascular resistance (PVR) 3.0 Wood units. Haemodynamic, clinical, echocardiographic, and biochemical assessments (including NT-proBNP, hs-CRP) were performed. The Heart Failure Survival Score (HFSS) was calculated. RESULTS: Estimated death rate was comparable between patients with no PH, passive PH, and reactive PH, despite the fact that the patients with reactive PH had the worst pulmonary haemodynamic scores (mean PAP 38.4 ± 7.8, PCWP 27 ± 7.4 mm Hg and PVR 4.8 ± 1.7 Wood units). In patients with reactive PH, in multifactor Cox analysis only the serum Na level influenced survival. According to the Kaplan-Meier method, patients with reactive PH, with mean PAP ≥ 41.4 mm Hg had the worst prognosis, estimated survival was: one year - 83%, two years - 65%. CONCLUSIONS: Reactive PH is common among patients with chronic HF listed to HTx (28%). It has no further influence on short-term prognosis as compared with patients with no PH and passive PH. Serum Na concentration and mean PAP ≥ 41.4 mm Hg influence the prognosis of patients with reactive PH.
Subject(s)
Heart Failure/diagnosis , Heart Transplantation , Hypertension, Pulmonary/complications , Adult , Chronic Disease , Female , Heart Failure/complications , Heart Failure/mortality , Heart Failure/therapy , Hemodynamics , Humans , Male , Middle Aged , Poland , Prognosis , Risk FactorsABSTRACT
INTRODUCTION: The assessment of prognosis is crucial for the clinical management of patients with heart failure (HF). OBJECTIVES: The aim of the study was to evaluate the usefulness of novel biomarkers for the assessment of prognosis in patients with HF, compared with a detailed assessment based on routine laboratory tests. PATIENTS AND METHODS: The study included 179 patients with HF. In all patients, routine laboratory tests were performed and selected biomarkers were measured (N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, growth hormone, myeloperoxidase, metaloproteinase 9, procollagen type III, soluble toll like receptor 2, insulin growth factor, and neutrophil gelatinase-associated lipocain). The primary endpoint was death or urgent heart transplantation, while the secondary endpoints encompassed primary endpoints plus cardioverter intervention or hospitalization for HF. RESULTS: The mean age of the study group was 52.5 years (91% were men). Most patients had advanced HF. During a 6-month follow-up, 21 primary endpoints and 63 secondary endpoints were recorded. A multiple regression analysis showed that of all laboratory variables and biomarkers, only uric acid and sodium were independent predictors of primary endpoints, and only estimated glomerular filtration rate had a predictive value for secondary endpoints. None of the biomarkers were a significant prognostic factor in the study population. CONCLUSIONS: Biomarkers do not outweigh the value of standard laboratory tests. Routine laboratory workup allows to assess multiorgan damage and provides the most significant prognostic data. Biochemical tests should remain the gold standard for the assessment of prognosis in patients with HF.
Subject(s)
Glomerular Filtration Rate , Heart Failure/diagnosis , Sodium/blood , Uric Acid/blood , Adult , Aged , Biomarkers , Female , Heart Failure/blood , Humans , Male , Middle Aged , PrognosisABSTRACT
BACKGROUND: Heart transplantation (HTx) is still the optimal treatment for refractory heart failure (HF). However, there is great disproportion between the number of donors and potential recipients. Several parameters are used in patient evaluation before HTx, but the qualification process still requires improvement. High-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) possess high prognostic value for patients with advanced HF. AIM: To assess the prognostic significance of NT-proBNP and hsCRP separately, as well as in combination, in a group of patients with advanced HF, considered for HTx. METHODS: Registry 632 patients referred for HTx in Poland (20032007). Following proper treatment correction and routine clinical evaluation (i.e. mean New York Heart Association [NYHA] classification 3.2 ± 0.6, heart rate 77 ± 15 bpm, systolic/diastolic blood pressure [SBP/DBP] 103/67 ± 15/11 mm Hg, left ventricular ejection fraction [LVEF] 22 ± 8%, serum Na+ 136 ± 4 mmol/L, NT-proBNP 3942 ± 5637 pg/mL, hsCRP 9 ± 22 mg/L levels, HFSS according to Aaronson 8 ± 1, etc.) patients were qualified for HTx. Based on ROC analysis (cut-off points for NT-proBNP 2435 pg/mL and hsCRP 2.4 mg/L) subjects were stratified into four subgroups: (1) non-elevated hsCRP ()/NT-proBNP () (n = 179); (2) non-elevated hsCRP ()/ /elevated NT-proBNP (+) (n = 92); (3) elevated hsCRP (+)/non-elevated NT-proBNP () (n = 159); and (4) elevated hsCRP (+)/ /NT-proBNP (+) (n = 202). The end point was defined as death/urgent HTx. The mean follow-up period was 601 days. RESULTS: In univariate regression analysis we confirmed that classical risk factors were independent predictors of end point: NYHA (HR = 2.311; p < 0.0001), heart rate (HR = 1.016; p = 0.0009), SBP (HR = 0.984; p = 0.0111), LVEF (HR = 0.951; p < 0.0001), serum Na+ (HR = 0.901; p < 0.0001), NT-proBNP (HR = 1.004; p = 0.0159), and hsCRP (HR = 1.010; p = 0.0002); HFSS (HR = 0.557; p < 0.0001). Frequency-of-events analysis revealed that patients in the hsCRP ()/ /NT-proBNP () subgroup presented with the best prognosis (13% of patients reached end point) followed by the hsCRP ()/ /NT-proBNP (+) subgroup, in which 24% of patients reached end point (Kaplan-Meier c2 = 8.5319; p = 0.0035) and the hsCRP (+)/NT-proBNP (+) subgroup (c2 = 42.0413; p < 0.0001), which was associated with the worst prognosis (39% of patients reached end point). CONCLUSIONS: The classical risk factors: NYHA class, heart rate, SBP, LVEF, HFSS, serum Na+, NT-proBNP, and hsCRP concentrations, proved to be valuable in the assessment of risk in advanced HF patients. However, concomitant evaluation of old markers: hsCRP and NT-proBNP, may become a good prognostic tool for identification of highest-risk patients among all referred for HTx. Such a new approach to risk stratification before HTx seems promising but requires further investigation.
Subject(s)
Biomarkers/blood , C-Reactive Protein/analysis , Heart Failure/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Adult , Heart Failure/blood , Heart Transplantation , Humans , Middle Aged , Prognosis , Risk FactorsABSTRACT
BACKGROUND: Pulmonary hypertension is a contradiction for heart transplantation (HTx). The aim of the study was to examine prognostic significance of pulmonary hemodynamic variables in patients with severe chronic heart failure (HF) considered for HTx. METHODS: Patients with HF were qualified to HTx in Poland. We measured pulmonary artery systolic pressure (PASP), pulmonary capillary wedge pressure (PCWP), transpulmonary gradient (TPG), cardiac output (CO), pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR). We performed biochemical evaluation, 6-min walking test, VO2max. Death or emergency HTx were assumed as the endpoints in the follow-up. Death or any kind of HTx were considered an end of observation. Survival analysis was conducted using Kaplan-Meier curves (long rank test with strait defined by terciles of analyzed hemodynamic parameters). RESULTS: Six hundred and fifty-eight patients were qualified to HTx between 2003 and 2007. The mean follow-up: 601 days. 87.8% male. Mean age was under 50, III and IV NYHA class. Mean PASP was 44.3 ± 16.9 mm Hg, TPG 10.0 ± 6.6 mm Hg and PVR 2.9 mm Hg, PCWP20.9 ± 9.3 mm Hg. PASP and PCWP had influence on survival or emergency HTx. There was a significant difference in survival between patients with PCWP > 25 mm Hg and PCWP < 25 mm Hg. The worst prognosis was with PASP higher than 50 mm Hg. One-, two-, and three-year survival was 75%, 58% and 48% compared to patients with PASP < 35 mm Hg (80%, 70%, and 68%, respectively). CONCLUSIONS: In patients qualified to HTx, pathological values of pulmonary hemodynamic parameters have a significant influence on survival. The worst prognosis have patients with PASP > 50 mm Hg, and PCWP > 25 mm Hg. Pulmonary hemodynamic parameters are important during allocation process to HTx.
Subject(s)
Heart Failure/surgery , Heart Transplantation , Hypertension, Pulmonary/physiopathology , Pulmonary Wedge Pressure/physiology , Female , Follow-Up Studies , Heart Failure/complications , Heart Failure/mortality , Humans , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/etiology , Incidence , Male , Middle Aged , Poland/epidemiology , Prognosis , Retrospective Studies , Survival Rate/trends , Time Factors , Vascular ResistanceABSTRACT
INTRODUCTION: Data regarding standardized trends in mortality from heart failure (HF) in the general population are limited. OBJECTIVES: The aim of the study was to evaluate trends in HF mortality in Poland in the years 1980-2010. PATIENTS AND METHODS: An analysis of a database of mortality records from 1980-2010 based on National Statistics was performed. Mortality trends for HF by age and sex were analyzed by polynomial or linear regression. RESULTS: Total crude numbers of HF deaths in 1980 were 21,519 and 23,008 for women and men, respectively, whereas, in 2010, there were 23,304 and 19,558. There was a significant change in mortality trends for HF, from a decline during the first phase of the study to an increase during the most recent years, 2005-2010 (P <0.005 for changes of trends for both sexes). The lowest value reached in 2005 constituted 47% and 41% of the baseline for women and men, respectively. These ratios increased to 59% and 52% in 2010. Stratification by age and sex brought similar results, with the exception of the youngest groups, which showed initial increases in the rates for the years 1980-1985. CONCLUSIONS: There was a significant decline in the rates of HF mortality in the Polish population for both men and women, showing a maximal reduction of about 50% around 2005. However, between 2005 and 2010, a significant increase in the rates of HF mortality was observed (crude difference equaled 12% for women and 11% for men). It is unknown whether this is a temporary or permanent trend, and the issue requires further investigation.
Subject(s)
Heart Failure/mortality , Age Distribution , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Poland/epidemiology , Sex Distribution , Survival RateABSTRACT
BACKGROUND: Most of the available data suggest that the risk of malignancy in solid organ recipients is higher than in the general population. In Poland, the prevalence rate for malignancy in the general population is about 1.02%. MATERIAL AND METHODS: At out Outpatient Clinic for patients after heart transplantation we analyzed all 324 patients transplanted from 1987-2011 for the presence of malignancies. The end-point of the analysis was determined by malignancy diagnosis, patient death, or end of the observation period (December 12, 2011). RESULTS: We detected 31 malignancies in 29 of 324 patients (8.95%). In 2 patients we found 2 types of malignancies. The dominant type of malignancy was pulmonary carcinoma, diagnosed in 11/29 (37.93%) patients. Skin carcinoma was recognized in 7 patients (24.14%). Fourteen (48.3%) patients died (12 men and 2 women): 5 of them in the course of pulmonary carcinoma (35.7%), 3 of skin carcinoma (21.4), 3 in the course of lymphoma, 1 in the course of renal carcinoma, 1 in the course of stomach carcinoma, 1 of colorectal carcinoma, and 1 of prostatic carcinoma. CONCLUSIONS: The risk of malignancy development is many times higher for HT patients than in the general population. The high incidence rate for pulmonary carcinoma in the analyzed group of patients was most likely related to smoking before transplantation and continuation of smoking after the procedure in the case of patients who received immunosuppressive therapy.
Subject(s)
Heart Transplantation/adverse effects , Neoplasms/epidemiology , Neoplasms/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Immunosuppressive Agents/adverse effects , Incidence , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Male , Middle Aged , Poland/epidemiology , Retrospective Studies , Risk Factors , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Smoking/adverse effects , Young AdultABSTRACT
BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro. METHODS: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. RESULTS: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. CONCLUSIONS: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members.
Subject(s)
Cardiomyopathy, Dilated/genetics , Cardiomyopathy, Dilated/pathology , Lamin Type A/genetics , Myoblasts/metabolism , Sequence Deletion , Adult , Animals , Arrhythmias, Cardiac/genetics , Arrhythmias, Cardiac/pathology , Cardiomyopathy, Dilated/ethnology , Cell Line , Cohort Studies , DNA Mutational Analysis , Genetic Association Studies , Genetic Predisposition to Disease , Heart Failure/genetics , Heart Failure/pathology , Heart Transplantation/methods , Heterozygote , Humans , Male , Mice , Middle Aged , Mutagenesis, Site-Directed , Myocardium/ultrastructure , Myocytes, Cardiac/pathology , Pedigree , Poland/epidemiology , Prevalence , Young AdultABSTRACT
AIMS: Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with stable heart failure (HF) with reduced LVEF. We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2). METHODS AND RESULTS: Sixty-two patients with HF and LVEF ≤ 35% were instrumented with a pulmonary artery catheter and randomly assigned (ratio 3:1) to receive an intravenous infusion of JNJ-39588146 or placebo. The main study was an ascending dose study of three doses (5, 15, and 30 ng/kg/min) of study drug or placebo administered in sequential 1 h intervals (3 h total). Statistically significant increases in CI and reduction in systemic vascular resistance (SVR) were observed with both the 15 ng/kg/min (2 h time point) and 30 ng/kg/min (3 h time point) doses of JNJ-39588146 without significant changes in heart rate (HR) or systolic blood pressure (SBP). No statistically significant reductions in pulmonary capillary wedge pressure (PCWP) were seen with any dose tested in the primary analysis, although a trend towards reduction was seen. CONCLUSION: In HF patients with reduced LVEF and CI, ascending doses of JNJ-39588146 were associated with progressive increases in CI and reductions in SVR without significant effects on PCWP, HR, or SBP. TRIAL REGISTRATION: NCT01120210.
Subject(s)
Corticotropin-Releasing Hormone/pharmacokinetics , Heart Failure/metabolism , Hemodynamics/drug effects , Stroke Volume/physiology , Urocortins/pharmacokinetics , Adult , Aged , Biomarkers/blood , Blood Pressure/drug effects , Cardiac Output/drug effects , Corticotropin-Releasing Hormone/pharmacology , Dose-Response Relationship, Drug , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Infusions, Intravenous , Male , Middle Aged , Pulmonary Wedge Pressure/drug effects , Urocortins/pharmacologyABSTRACT
BACKGROUND: Based on the results of clinical trials, the prognosis for patients with severe heart failure (HF) has improved over the last 20 years. However, clinical trials do not reflect 'real life' due to patient selection. Thus, the aim of the POLKARD-HF registry was the analysis of survival of patients with refractory HF referred for orthotopic heart transplantation (OHT). METHODS: Between 1 November 2003 and 31 October 2007, 983 patients with severe HF, referred for OHT in Poland, were included into the registry. All patients underwent routine clinical and hemodynamic evaluation, with NT-proBNP and hsCRP assessment. Death or an emergency OHT were assumed as the endpoints. The average observation period was 601 days. Kaplan-Meier curves with log-rank and univariate together with multifactor Cox regression model the stepwise variable selection method were used to determine the predictive value of analyzed variables. RESULTS: Among the 983 patients, the probability of surviving for one year was approximately 80%, for two years 70%, and for three years 67%. Etiology of the HF did not significantly influence the prognosis. The patients in NYHA class IV had a three-fold higher risk of death or emergency OHT. The univariate/multifactor Cox regression analysis revealed that NYHA IV class (HR 2.578, p < 0.0001), HFSS score (HR 2.572, p < 0.0001) and NT-proBNP plasma level (HR 1.600, p = 0.0200), proved to influence survival without death or emergency OHT. CONCLUSIONS: Despite optimal treatment, the prognosis for patients with refractory HF is still not good. NYHA class IV, NT-proBNP and HFSS score can help define the highest risk group. The results are consistent with the prognosis of patients enrolled into the randomized trials.
Subject(s)
Heart Failure/surgery , Heart Transplantation , Waiting Lists , Adult , Biomarkers/blood , C-Reactive Protein/analysis , Chronic Disease , Female , Heart Failure/blood , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Heart Transplantation/mortality , Hemodynamics , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Poland/epidemiology , Prognosis , Proportional Hazards Models , Registries , Risk Assessment , Risk Factors , Severity of Illness Index , Survival Rate , Time Factors , Waiting Lists/mortalityABSTRACT
BACKGROUND: Coronary artery disease (CAD) is a complex disorder accounting for the majority of cardiovascular deaths and morbidity. It is believed that genetic factors explain part of the excessive risk of major adverse cardiac events (MACE) after percutaneous coronary intervention (PCI). AIM: To evaluate the influence on long-term prognosis of some genetic polymorphisms affecting renin-angiotensin system, inflammatory response, beta-2 adrenergic receptor, nitric oxide and platelets activity in patients with stable CAD undergoing routine PCI. METHODS: The study population consisted of 110 consecutive male patients with stable angina undergoing elective, single-vessel PCI. Genotyping was performed by polymerase chain reaction and restriction fragment length polymorphism-based techniques. Follow-up data were obtained by postal questionnaires regarding survival, myocardial infarction and revascularisation procedures. The control group consisted of 78 healthy males. RESULTS: Compared to controls, the distribution of polymorphisms among patients differed with regard to interleukin-1 receptor antagonist and CD14 variants. Patients who had PCI during follow-up in comparison with the remaining patients had a similar genetic profile, but higher triglycerides (1.9 vs 1.5 mmol/L, p = 0.01) and atherogenic index (3.8% vs 3.1%, p = 0.03) and lower percentage of HDL (21.8% vs 25.0%, p = 0.02). Among subjects with any revascularisation procedures, a similar clinical profile was observed. However, they differed from those without any procedures regarding the distribution of angiotensinogen M235T variants (MM%/TM%/TT%) 28%/64%/8% vs 19%/50%/31%, p = 0.048. Stratification for myocardial infarction showed association with selectin E variants (AA%/AC%/CC%) 57.1%/28.6%/14.3% vs 78.8%/21.2%/0%, p = 0.055 and higher triglycerides (2.11 vs 1.57 mmol/L, p = 0.055). CONCLUSIONS: Although we cannot exclude the role of polymorphism in angiotensinogen and selectin E genes, the prognosis of patients post-PCI in our study was mainly influenced by risk factors related to lipid metabolisms.
Subject(s)
Angina, Stable/therapy , Angioplasty/methods , Polymorphism, Genetic/genetics , Adult , Aged , Angina, Stable/genetics , Case-Control Studies , Follow-Up Studies , Genetic Markers , Genetic Predisposition to Disease , Genotype , Humans , Lipopolysaccharide Receptors/genetics , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Prospective Studies , Receptors, Adrenergic, beta-2/genetics , Receptors, Interleukin-1/genetics , Renin-Angiotensin System/genetics , Risk Factors , Surveys and QuestionnairesABSTRACT
BACKGROUND: It is difficult to define the optimal management of elderly heart failure (HF) patients with complex comorbidities. Thus, comprehensive characterisation of HF patients constitutes a crucial pre-condition for the successful management of this fragile population. AIM: To analyse the 'real life' HF patients, including the evaluation of their health conditions, management and their use of public health resources. METHODS AND RESULTS: We examined 822 consecutive patients diagnosed with HF in NYHA classes II-IV in primary care practices. The mean age was 68.5 years, and 56% were male. Only 23% of the patients who were of pre-retirement age remained professionally active. Ischaemic or hypertension aetiology was found in 90% of participants. Nearly all patients had multiple comorbidities. Most patients received converting enzyme inhibitors (88%) and beta-blockers (77%), 60% of them both, although dosing was frequently inadequate. During the six months preceding the study, 31% had cardiovascular hospitalisation and 66% required unscheduled surgery visits. CONCLUSIONS: The real life HF population differs from trial populations. Most of the real life patients who had not yet reached retirement age were professionally inactive, mainly due to a disability caused by cardiovascular conditions. Moreover, extremely few participants were free from any comorbidity. Compared to 20th century Polish data, there has been an improvement in the overall quality of HF-recommended pharmacotherapy. It must be stressed, however, that the percentage of those on optimal dosage remains unsatisfactory.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiovascular Agents/therapeutic use , Heart Failure/epidemiology , Adult , Aged , Aged, 80 and over , Comorbidity , Drug Therapy, Combination , Female , Heart Failure/drug therapy , Heart Failure/physiopathology , Humans , Male , Middle Aged , Poland/epidemiology , Primary Health CareABSTRACT
BACKGROUND: Plasma B-type natriuretic peptide (BNP) levels are closely related to symptoms in left ventricle (LV) systolic heart failure, although marked regarding heterogeneity levels among subjects are reported. AIMS: To assess the influence of right ventricle on plasma BNP in the patients with different grades of its overload secondary to severe mitral valve stenosis (MVS). METHODS: Plasma BNP was evaluated in MVS patients (n = 27) before valve replacement and during follow-up (FUV) 401 ± 42 days after operation. RESULTS: Initial examination showed severe MVS (0.9 ± 0.2 cm²), left atrial enlargement (LAI 30 ± 4.5 mm m⻲), right ventricle diastolic dilatation (RVDI 16 ± 3.6 mm m⻲), normal LV size/function and elevated BNP levels (166 ± 137 pg ml⻹). FUV examination revealed a significant reduction in LAI (27 ± 2.2 mm m⻲), RVDI (14 ± 1.6 mm m⻲) and BNP levels (80 ± 35 pg ml⻹). The regression analysis of the initial parameters found RVDI to be the strongest predictor (R² = 0.61; P<0.0001) for BNP level, whereas RVDI reduction was the strongest factor for BNP decrease (R² = 0.65; P<0.0001) during FUV. CONCLUSIONS: Right ventricle should be taken into account as a potential important source of plasma BNP owing to the fact that LV size and function are well preserved in MVS patients. RVDI determines BNP plasma levels whereas after MVS removal, the RVDI reduction predicts BNP level decrease.
Subject(s)
Heart Failure/etiology , Heart Valve Prosthesis Implantation , Hypertrophy, Right Ventricular/etiology , Mitral Valve Stenosis/surgery , Natriuretic Peptide, Brain/blood , Rheumatic Heart Disease/surgery , Aged , Biomarkers/blood , Case-Control Studies , Down-Regulation , Female , Heart Failure/blood , Heart Failure/diagnostic imaging , Heart Failure/physiopathology , Heart Ventricles/metabolism , Humans , Hypertrophy, Right Ventricular/blood , Hypertrophy, Right Ventricular/diagnostic imaging , Hypertrophy, Right Ventricular/physiopathology , Male , Middle Aged , Mitral Valve Stenosis/blood , Mitral Valve Stenosis/complications , Mitral Valve Stenosis/diagnostic imaging , Mitral Valve Stenosis/physiopathology , Poland , Regression Analysis , Rheumatic Heart Disease/blood , Rheumatic Heart Disease/complications , Rheumatic Heart Disease/diagnostic imaging , Rheumatic Heart Disease/physiopathology , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome , Ultrasonography , Ventricular Function, Left , Ventricular Function, RightABSTRACT
BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia among patients (pts) with heart failure and has significant influence on survival. AIM OF THE STUDY: to assess prognosis of pts with refractory heart failure (HF) qualified for heart transplantation (HTX). MATERIAL/METHODS: 872 pts (107 W and 765 M) were qualified for HTX between Dec 2003 and Oct 2007. Patient's death or super urgent heart transplantation were considered the end point in Kaplan-Meier survival curves. RESULTS: 680 pts were on sinus rhythm (SR) and 192(22.0%) had atrial fibrillation (AF). During follow-up (1-1464 days, mean 550 days) 155 pts (17.7%) died, 17.65% with SR and 18.23% with AF (ns). EF - mean 21,6 (SR) and 21,8 (FA), NYHA 3,1 (SR), NTproBNP- mean 3635, 4 (SR) and 4349,4 (FA), Arronson - mean 7,8 (SR) and 7,7 (FA). There were no significant differences between groups. We analyzed influence of heart rate (Kaplan-Maier method) on survival. The pts were divided according to HR: gr.I <70/min, gr II 71-89/min, gr III >90/min. The shortest survival rate was noticed in group III. There was no difference in survival between group I and II. CONCLUSIONS: The prognosis for patients qualified for heart transplant does not depend on the type of the dominant cardiac rhythm (atrial fibrillation or sinus rhythm). The prognosis is significantly better for those patients whose basic, resting heart rate does not exceed 90 bpm regardless of the rhythm type.